VivoSeq
Other

Efficacy

0

Pipeline Programs

158

Active Trials

199

Companies Involved

Efficacy is an early-stage landscape with 0 programs across 199 companies. The most active players are Novartis, GSK, AstraZeneca.

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

63/100

Mech. Concentration

N/A

Completion Rate

84/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

1,199

clinical trials

Completed760 · 63%
Unknown status139 · 12%
Terminated91 · 8%
Recruiting76 · 6%
Not yet recruiting45 · 4%
Withdrawn45 · 4%
Other43 · 4%

Trial Activity

1199 trials

The Efficacy of Allo-HSCT in ND HR-CBF-AML
Recruiting·RRuijin Hospital·N/A·NCT06458244·90 enrolled
Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety
Recruiting··Phase 1·NCT07453862·20 enrolled
Page 1 of 80

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)